Company research
Quantum Biopharma Ltd.
CIK 1771885Updated Nov 14, 2026
Historical securities (1)
QNTM · NEO · equity · closed Oct 1, 2024QNTM price & chart
Loading TradingView…
CSE:QNTM on TradingView ↗About the company
Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (“Quantum” or the “Company”) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity that has been shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
In the news
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment ↗
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial ↗
Quantum BioPharma Announces Closing of Debt Settlement ↗
Financials
FY 2025 · USDSource
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossUSD | — | — | -4,747,600Source | -4,015,327Source | -9,766,327Source | -3,352,499Source | -8,739,881Source | -2,091,425Source | — | — | — | -23,606,828Source |
| Additional Financial Items | ||||||||||||
| AdjustmentsForFinanceIncomeUSD | — | — | — | — | — | — | -414,189Source | -548,547Source | -1,491,001Source | -4,663,014Source | 663,698Source | 7,431,656Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | — | — | — | — | — | — | -177,476Source | -1,049,365Source | 1,178,497Source | — | — | — |
| AdjustmentsForSharebasedPaymentsUSD | — | — | — | — | — | — | 291,272Source | 57,743Source | 2,945,502Source | — | 16,702Source | 1,531,258Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | — | — | — | — | — | — | — | — | — | — | — | 934,100Source |
| GeneralAndAdministrativeExpenseUSD | — | — | — | 3,250,030Source | — | 2,310,283Source | — | — | — | 9,410,097Source | 9,032,724Source | 14,450,094Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | 23,325Source | 14,662Source | 113,862Source | 63,586Source | 189,054Source | 143,071Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | — | — | — | — | — | — | 443,526Source | 286,944Source | 2,113,386Source | — | — | — |
| ProceedsFromIssuingSharesUSD | — | — | — | — | — | — | 0Source | 296,437Source | 338,331Source | 10,670,618Source | 34Source | 0Source |
| ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD | — | — | — | — | — | — | 1,181,499Source | — | 1,181,499Source | -6,189,077Source | 443,138Source | 158,036Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 250,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | 3,041,374Source | 3,250,030Source | 3,313,275Source | 2,310,283Source | 1,328,111Source | 1,919,212Source | 9,047,918Source | — | — | — |
| Additional Financial Items | ||||||||||||
| ApplicableTaxRatenumber | — | — | — | — | — | — | — | — | 0.27Source | 0.27Source | 0.27Source | 0.27Source |
| DeferredTaxExpenseIncomeUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| DepreciationAndAmortisationExpenseUSD | — | — | 145,336Source | 120,814Source | 141,383Source | 136,813Source | 129,690Source | 120,141Source | 545,780Source | 490,571Source | 2,506,316Source | 4,537,415Source |
| DepreciationRightofuseAssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 114,907Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | — | — | 996,194Source | 65,424Source | 849,584Source | 111,524Source | 291,272Source | 57,743Source | 2,945,502Source | 152,214Source | 3,835,475Source | 1,531,258Source |
| FinanceCostsUSD | — | — | 91,570Source | 10,371Source | 116,962Source | 8,357Source | 22,168Source | 12,414Source | 158,063Source | 33,017Source | 299Source | 48,822Source |
| GeneralAndAdministrativeExpenseUSD | — | — | — | 3,250,030Source | — | 2,310,283Source | — | — | — | 9,410,097Source | 9,032,724Source | 14,450,094Source |
| InterestExpenseUSD | — | — | — | — | — | — | — | — | — | 9,343Source | 24,288Source | 149,906Source |
| InterestExpenseOnLeaseLiabilitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 19,062Source |
| OtherIncomeUSD | — | — | 6,202Source | 0Source | 1,935,956Source | 0Source | 7,060Source | 0Source | 1,946,491Source | 3,989Source | — | — |
| ProfessionalFeesExpenseUSD | — | — | 735,946Source | 618,906Source | 1,602,570Source | 958,377Source | 355,722Source | 858,423Source | 3,278,735Source | 3,074,130Source | 3,248,233Source | 5,208,356Source |
| ProfitLossAttributableToNoncontrollingInterestsUSD | — | — | -4,747,600Source | -4,015,327Source | -9,766,327Source | -3,352,499Source | -8,739,881Source | -2,091,425Source | -26,956,840Source | -14,915,529Source | -18,230,588Source | — |
| ProfitLossFromOperatingActivitiesUSD | — | — | -4,678,127Source | -4,181,070Source | -4,853,439Source | -3,456,606Source | -3,397,423Source | -2,257,356Source | -15,302,374Source | — | — | -27,429,611Source |
| ResearchAndDevelopmentExpenseUSD | — | — | 495,223Source | 744,802Source | 549,197Source | 897,986Source | 1,648,350Source | 160,260Source | 2,763,174Source | 6,083,378Source | 3,859,178Source | 6,910,844Source |
| RevenueFromInterestUSD | — | — | — | — | — | — | — | — | — | — | 568,919Source | 183,037Source |
| SellingExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 616,002Source |
| ProfitLossAttributableToOwnersOfParent | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
qntmex99-1.htm · 6-K · 2026-11-12
Exhibit 99.1 Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three and nine months ended September 30, 2026, and 2025 [expressed in United States dollars] QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [unaudited] [expressed in United States dollars] As at September 30, …
Read attachment ↗qntmex99-2.htm · 6-K · 2026-11-12
Exhibit 99.2 QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS As used in this management’s discussion and analysis of financial condition and results of operations (this “MD&A”), unless the context indicates or requires otherwise, all references to the “Company”, “Quantum”, “Quantum BioPharma”, “we”, “us” or “our” refer to Quantum BioPharma Ltd., together with our subsidiaries, on a consolidated basis as …
Read attachment ↗qntmex99-1.htm · 6-K · 2026-09-17
Exhibit 99.1 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. QUANTUM BIOPHARMA PROVIDES CORPORATE UPDATE Toronto, Ontario - March 7, 2025 -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate…
Read attachment ↗qntmex99-2.htm · 6-K · 2026-09-17
Exhibit 99.2 Quantum BioPharma Ltd. Announces Corporate Updates Toronto, Ontario - October 29, 2025 - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today anno…
Read attachment ↗qntmex99-1.htm · 6-K · 2026-09-02
Exhibit 99.1 Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange Toronto, Ontario -- September 1, 2026 -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“ Quantum BioPharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders…
Read attachment ↗qntmex99-1.htm · 6-K · 2026-08-13
Exhibit 99.1 Quantum Biopharma Ltd. (formerly, FSD Pharma Inc.) Condensed consolidated interim financial statements For the three and six months ended June 30, 2026, and 2025 [expressed in United States dollars] QUANTUM BIOPHARMA LTD. (FORMERLY, FSD PHARMA INC.) CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [unaudited] [expressed in United States dollars] As at June 30, December 31, …
Read attachment ↗